Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 5 | 1 |
| List of Figures | 5 | 1 |
| RXi Pharmaceuticals Corporation Snapshot | 6 | 1 |
| RXi Pharmaceuticals Corporation Overview | 6 | 1 |
| Key Information | 6 | 1 |
| Key Facts | 6 | 1 |
| RXi Pharmaceuticals Corporation Research and Development Overview | 7 | 3 |
| Key Therapeutic Areas | 7 | 3 |
| RXi Pharmaceuticals Corporation Pipeline Review | 10 | 2 |
| Pipeline Products by Stage of Development | 10 | 1 |
| Pipeline Products Monotherapy | 11 | 1 |
| RXi Pharmaceuticals Corporation Pipeline Products Glance | 12 | 5 |
| RXi Pharmaceuticals Corporation Clinical Stage Pipeline Products | 12 | 1 |
| Phase II Products/Combination Treatment Modalities | 12 | 1 |
| Phase I Products/Combination Treatment Modalities | 13 | 1 |
| RXi Pharmaceuticals Corporation Early Stage Pipeline Products | 14 | 1 |
| IND/CTA Filed Products/Combination Treatment Modalities | 14 | 1 |
| Preclinical Products/Combination Treatment Modalities | 15 | 1 |
| Discovery Products/Combination Treatment Modalities | 16 | 1 |
| RXi Pharmaceuticals Corporation Drug Profiles | 17 | 20 |
| diphencyprone | 17 | 1 |
| Product Description | 17 | 1 |
| Mechanism of Action | 17 | 1 |
| R&D Progress | 17 | 1 |
| RXI-109 | 18 | 1 |
| Product Description | 18 | 1 |
| Mechanism of Action | 18 | 1 |
| R&D Progress | 18 | 2 |
| RNAi Oligonucleotide to Inhibit CTGF for PVR | 20 | 1 |
| Product Description | 20 | 1 |
| Mechanism of Action | 20 | 1 |
| R&D Progress | 20 | 1 |
| RNAi Oligonucleotide Inhibiting MDM2 for Retinoblastoma | 21 | 1 |
| Product Description | 21 | 1 |
| Mechanism of Action | 21 | 1 |
| R&D Progress | 21 | 2 |
| RNAi Oligonucleotide to Inhibit SOD-1 for ALS | 23 | 1 |
| Product Description | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| R&D Progress | 23 | 2 |
| RNAi Oligonucleotide to Inhibit VEGF for Macular Degeneration | 25 | 1 |
| Product Description | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| R&D Progress | 25 | 1 |
| RXI-209 | 26 | 1 |
| Product Description | 26 | 1 |
| Mechanism of Action | 26 | 1 |
| R&D Progress | 26 | 1 |
| bevasiranib sodium | 27 | 1 |
| Product Description | 27 | 1 |
| Mechanism of Action | 27 | 1 |
| R&D Progress | 27 | 1 |
| MMP-26051 | 28 | 1 |
| Product Description | 28 | 1 |
| Mechanism of Action | 28 | 1 |
| R&D Progress | 28 | 1 |
| MMP-26052 | 29 | 1 |
| Product Description | 29 | 1 |
| Mechanism of Action | 29 | 1 |
| R&D Progress | 29 | 1 |
| RNAi Oligonucleotide to Inhibit Angiopoietin-2 for Retinal Disease and Cancer | 30 | 1 |
| Product Description | 30 | 1 |
| Mechanism of Action | 30 | 1 |
| R&D Progress | 30 | 1 |
| RNAi Oligonucleotide to Inhibit HIF-1 Alpha for Retinal Disease and Cancer | 31 | 1 |
| Product Description | 31 | 1 |
| Mechanism of Action | 31 | 1 |
| R&D Progress | 31 | 1 |
| RNAi Oligonucleotide to Inhibit ICAM-1 for Retinal Diseases and Cancer | 32 | 1 |
| Product Description | 32 | 1 |
| Mechanism of Action | 32 | 1 |
| R&D Progress | 32 | 1 |
| RNAi Oligonucleotides to Inhibit Complement C3 for Ophthalmology | 33 | 1 |
| Product Description | 33 | 1 |
| Mechanism of Action | 33 | 1 |
| R&D Progress | 33 | 1 |
| RNAi Oligonucleotides to Inhibit TNF-alpha for Autoimmune Disorders | 34 | 1 |
| Product Description | 34 | 1 |
| Mechanism of Action | 34 | 1 |
| R&D Progress | 34 | 1 |
| TRY-26071 | 35 | 1 |
| Product Description | 35 | 1 |
| Mechanism of Action | 35 | 1 |
| R&D Progress | 35 | 1 |
| TRY-26077 | 36 | 1 |
| Product Description | 36 | 1 |
| Mechanism of Action | 36 | 1 |
| R&D Progress | 36 | 1 |
| RXi Pharmaceuticals Corporation Pipeline Analysis | 37 | 6 |
| RXi Pharmaceuticals Corporation Pipeline Products by Target | 37 | 2 |
| RXi Pharmaceuticals Corporation Pipeline Products by Route of Administration | 39 | 1 |
| RXi Pharmaceuticals Corporation Pipeline Products by Molecule Type | 40 | 1 |
| RXi Pharmaceuticals Corporation Pipeline Products by Mechanism of Action | 41 | 2 |
| RXi Pharmaceuticals Corporation Recent Pipeline Updates | 43 | 8 |
| RXi Pharmaceuticals Corporation Dormant Projects | 51 | 1 |
| RXi Pharmaceuticals Corporation Discontinued Pipeline Products | 52 | 1 |
| Discontinued Pipeline Product Profiles | 52 | 1 |
| bevasiranib sodium | 52 | 1 |
| RXi Pharmaceuticals Corporation Locations And Subsidiaries | 53 | 1 |
| Head Office | 53 | 1 |
| Appendix | 54 | 2 |
| Methodology | 54 | 1 |
| Coverage | 54 | 1 |
| Secondary Research | 54 | 1 |
| Primary Research | 54 | 1 |
| Expert Panel Validation | 54 | 1 |
| Contact Us | 54 | 1 |
| Disclaimer | 55 | 1 |